RxDoctor Payments Data

Marie Bissell, APRN

Gerontology · Lincoln, NENPI 1922393776

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 48.0% of the total.

$510in general payments, 2019–2025

Across 6 payments — averaging $85.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$245
  • Neurocrine Biosciences, Inc.$124
  • Otsuka America Pharmaceutical, Inc.$91
  • Solventum Corporation$25
  • Astellas Pharma US Inc$25

What the payments were for

  • Food & beverage$510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510 in reported general payments places this provider in the 55th percentile of 21 gerontology providers in Nebraska.

See all gerontology providers in Nebraska

Medicare billing

Part B allowed, 2024
$328,944
Medicare patients
826
Services billed
3,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole66$77,816
Invega SustennaPaliperidone Palmitate11$40,585
EliquisApixaban62$28,055
MyrbetriqMirabegron53$18,264
XareltoRivaroxaban29$12,386
TrintellixVortioxetine Hydrobromide44$11,401
JanuviaSitagliptin Phosphate17$9,811
Memantine Hcl180$8,478
Combivent RespimatIpratropium/Albuterol Sulfate16$8,203
Quetiapine Fumarate480$8,012
Clozapine77$7,052
Duloxetine Hcl147$6,652
Divalproex Sodium191$6,363
Breo ElliptaFluticasone/Vilanterol14$6,077
Sertraline Hcl448$5,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$91$77,81666 claims
Astellas Pharma US IncMyrbetriq$25$18,26453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 21 gerontology providers in Nebraska.

Other gerontology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →